Skip to main navigation Skip to search Skip to main content

Insights into the L,D-Transpeptidases and D,D-carboxypeptidase of mycobacterium abscessus: Ceftaroline, imipenem, and novel diazabicyclooctane inhibitors

  • Khalid M. Dous
  • , Sebastian G. Kur
  • , Magdalena A. Taracil
  • , Tracey Bonfield
  • , Christopher R. Bethe
  • , Melissa D. Barne
  • , Suresh Selvaraju
  • , Ayman M. Abdelhame
  • , Barry N. Kreiswirt
  • , W. Henry Boom
  • , Shannon H. Kasperbaue
  • , Charles L. Dale
  • , Robert A. Bonomo
  • Case Western Reserve University
  • Mount Sinai National Jewish Respiratory Institute
  • Louis Stokes Cleveland Department of Veterans Affairs Medical Center
  • National Jewish Health

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins (M. abscessus L,Dtranspeptidases 1 to 5 [LdtMab1to LdtMab5] and D,D-carboxypeptidase) that are targeted by β-lactam antibiotics. A challenge to this approach is the presence of chromosomally encoded β-lactamase (BlaMab). Using a mechanism-based approach, we found that a novel ceftaroline-imipenem combination effectively lowered the MICs of M. abscessus isolates (MIC50≤ 0.25 μg/ml; MIC90 ≤0.5 μg/ml). Combining ceftaroline and imipenem with a β-lactamase inhibitor, i.e., relebactam or avibactam, demonstrated only a modest effect on susceptibility compared to each of the β-lactams alone. In steady-state kinetic assays, BlaMabexhibited a lower Ki app(0.30 ± 0.03 μM for avibactam and 136 ± 14 μM for relebactam) and a higher acylation rate for avibactam (k2/K = 3.4 × 105±0.4 × 105M-1s-1for avibactam and 6 × 102± 0.6 × 102M-1s-1for relebactam). The kcat/Kmwas nearly 10-fold lower for ceftaroline fosamil (0.007 ± 0.001 μM-1s-1) than for imipenem (0.056 ± 0.006 μM-1s-1). Timed mass spectrometry captured complexes of avibactam and BlaMab, LdtMab1,LdtMab2,LdtMab4,and D,D-carboxypeptidase, whereas relebactam bound only BlaMab,LdtMab1,and LdtMab2.Interestingly, LdtMab1,LdtMab2,LdtMab4,LdtMab5,and D,D-carboxypeptidase bound only to imipenem when incubated with imipenem and ceftaroline fosamil. We next determined the binding constants of imipenem and ceftaroline fosamil for LdtMab1,LdtMab2,LdtMab4,and LdtMab5and showed that imipenem bound >100-fold more avidly than ceftaroline fosamil to LdtMab1and LdtMab2(e.g., Ki appor Kmof LdtMab1= 0.01 ±0.01μM for imipenem versus 0.73±0.08μM for ceftaroline fosamil). Molecular modeling indicates that LdtMab2readily accommodates imipenem, but the active site must widen to ≥8 Å for ceftaroline to enter. Our analysis demonstrates that ceftaroline and imipenem binding to multiple targets (L,Dtranspeptidases and D,D-carboxypeptidase) and provides a mechanistic rationale for the effectiveness of this dual -lactam combination in M. abscessus infections.

Original languageEnglish
Article numbere00098-20
JournalAntimicrobial Agents and Chemotherapy
Volume64
Issue number8
DOIs
StatePublished - Aug 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antibiotic resistance
  • Antibiotics
  • Bacteria
  • Ceftaroline
  • Diazabicyclooctane
  • Imipenem
  • Inhibitor
  • Mycobacteria
  • Mycobacterium abscessus

Fingerprint

Dive into the research topics of 'Insights into the L,D-Transpeptidases and D,D-carboxypeptidase of mycobacterium abscessus: Ceftaroline, imipenem, and novel diazabicyclooctane inhibitors'. Together they form a unique fingerprint.

Cite this